Approval of the implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems extends the Germany-based company’s cardiac rhythm portfolio with novel technologies designed to support physiology-driven therapies and improve day-to-day clinical workflows.

Biotronik said the new Sky family of devices introduces solutions to address a broad range of clinical challenges. Those include left bundle branch area pacing (LBBAP). The system features a new anti-tachycardia pacing (ATP) suite to expand atrial and ventricular ATP options as well. It continues to offer Biotronik’s DX single-lead technology for atrial sensing without an additional atrial lead.